论文部分内容阅读
复发性尿结石患者钙盐沉着的可能性似取决于尿内草酸钙和/或磷酸钙的超饱和度及其尿抑制物活性之间的平衡。已证明磷酸盐可减少患者的尿钙量,并增加尿焦磷酸盐的排泄量。后者在正常情况下,是抑制草酸钙结石形成的因素之一。某些报道指出,口服磷酸盐对预防尿结石具有良效,但有人对此持否定意见。本文报告一组反复发作的特发性钙石症患者,在口服正磷酸盐治疗后,定期随访长达4年的结果。患者共38例,均男性。其中14例为纯草酸钙结石,18例为草酸钙/磷酸钙混合性结石,余6例未作结石分析。治疗开始予病人磷酸盐片每日4次、每次半片口服,总量每天1克(每片含酸性磷酸钠68.1％、重碳酸钠9.5％、重碳酸钾3.5％,剂量为500mg。同时每片含
The likelihood of calcium deposition in patients with recurrent urolithiasis likely to depend on the balance between the hyper-saturation of urinary calcium oxalate and / or calcium phosphate and its urinary inhibitor activity. Phosphates have been shown to reduce urinary calcium in patients and increase urinary pyrophosphate excretion. The latter under normal circumstances, is one of the factors that inhibit the formation of calcium oxalate stones. Some reports point out that oral phosphate is good for the prevention of urinary stones, but some people hold a negative opinion. This article reports the recurrence of a group of patients with idiopathic calculi that are regularly followed up to 4 years after oral orthophosphate treatment. A total of 38 patients were male. Among them, 14 cases were pure calcium oxalate stones, 18 cases were calcium oxalate / calcium phosphate mixed stones, and the remaining 6 cases were not analyzed by stones. Treatment began to patients with phosphate tablets 4 times a day, each half a tablet orally, the total amount of 1 gram per day (each containing acidic sodium phosphate 68.1%, 9.5% sodium bicarbonate, potassium bicarbonate 3.5%, the dose of 500mg. Tablet containing